ArticleBMC pregnancy and childbirth2026
Development of a predictive model for preeclampsia utilizing time-of-flight mass spectrometry based on novel nanomaterials integrated with machine learning.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPreeclampsia (PE) is a serious complication of pregnancy, causing irreversible damage to multiple systems and organs of both mother and baby, and can even be life-threatening. Early diagnosis and intervention are key to improving maternal and fetal outcomes. Traditional diagnostic methods primarily rely on clinical symptoms and relatively single laboratory indicators, suffering from issues such as low sensitivity and insufficient specificity. Treatment is limited to symptomatic drug therapy for hypertension, and apart from terminating the pregnancy, there is a lack of effective treatment options. In recent years, Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) has shown great potential in disease biomarker screening due to its advantages of high sensitivity, high throughput, and rapid analysis.
methodsThis study utilized MALDI-TOF MS technology based on novel inorganic nanosilica material, combined with high-throughput multi-omics(proteomics, peptidomics and metabolomics) analysis, to perform machine learning modeling and optimization analysis on 159 samples from the First People's Hospital of Yunnan Province.
resultsTesting on the validation cohort showed an AUC value as high as 0.93 for preeclampsia detection, with the model's efficiency and accuracy surpassing traditional diagnostic methods. Furthermore, the machine learning model analysis identified 20 potential biomarkers associated with preeclampsia.
conclusionsBy constructing a diagnostic model for preeclampsia onset, this study can provide a basis for exploring the pathological mechanisms of preeclampsia. Simultaneously, it offers a novel technical approach for the screening and prediction of preeclampsia, holding significant clinical application value.
Indexed as
Identifiers
42387345What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.